|
Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement
|
06 May 2010 |
|
Bayer achieves strong gains in sales and earnings
|
30 April 2010 |
|
Bayer HealthCare Marks 2010 World Hemophilia Day with EUR 250,000 Contribution
|
19 April 2010 |
|
Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII
|
26 January 2010 |
|
Bayer to discontinue the LIPLONG study
|
26 January 2010 |
|
Bayer starts pivotal Phase III trial with Florbetaben
|
01 December 2009 |
|
Bayer Starts Phase III Trial with Florbetaben
|
01 December 2009 |
|
Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer
|
23 October 2009 |
|
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer
|
23 October 2009 |
|
Nexavar® Demonstrates 74 Percent Improvement in Progression-Free Survival
|
24 September 2009 |
|
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
|
21 September 2009 |
|
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress
|
21 September 2009 |
|
Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.
|
03 September 2009 |
|
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
|
31 August 2009 |
|
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban
|
31 August 2009 |
|
Bayer acquires exclusive rights to Bioton's insulin SciLin®
|
10 July 2009 |
|
Bayer submits first-in-class estradiol-based oral contraceptive for approval in the US
|
09 July 2009 |
|
Bayer files patent infringement lawsuit against Teva
|
02 July 2009 |
|
Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets
|
30 June 2009 |
|
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
|
02 June 2009 |